Redburn Partners analyst Bianca Dallal reinstates WPP (NYSE:WPP) with a Neutral.
Johnson & Johnson’s Clock 12% Q4 Revenue Growth, Cancer and Crohn’s Disease Drugs Account as Largest Sellers
Johnson & Johnson's Q4 2023 performance, with adjusted earnings up 11.7%, sales at $21.4 billion, and key insights into pharmaceutical and MedTech segments.